Altimmune (ALT) Competitors

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Do insiders & institutionals have more ownership in AMPH or ALT?

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is AMPH or ALT more profitable?

Amphastar Pharmaceuticals has a net margin of 21.80% compared to Altimmune's net margin of -199,076.92%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	21.80%	26.44%	11.89%
Altimmune	-199,076.92%	-55.81%	-50.60%

Which has higher earnings and valuation, AMPH or ALT?

Amphastar Pharmaceuticals has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$731.97M	1.50	$137.54M	$3.06	7.51
Altimmune	$20K	16,943.08	-$88.45M	-$1.34	-3.28

Which has more volatility & risk, AMPH or ALT?

Amphastar Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Does the media favor AMPH or ALT?

In the previous week, Amphastar Pharmaceuticals had 9 more articles in the media than Altimmune. MarketBeat recorded 11 mentions for Amphastar Pharmaceuticals and 2 mentions for Altimmune. Amphastar Pharmaceuticals' average media sentiment score of 1.13 beat Altimmune's score of 0.91 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor AMPH or ALT?

Amphastar Pharmaceuticals received 330 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.94% of users gave Altimmune an outperform vote while only 65.88% of users gave Amphastar Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amphastar Pharmaceuticals	Outperform Votes 392 65.88%	Underperform Votes 203 34.12%
Altimmune	Outperform Votes 62 72.94%	Underperform Votes 23 27.06%

Do analysts rate AMPH or ALT?

Amphastar Pharmaceuticals presently has a consensus price target of $43.50, suggesting a potential upside of 89.21%. Altimmune has a consensus price target of $20.83, suggesting a potential upside of 373.48%. Given Altimmune's stronger consensus rating and higher possible upside, analysts plainly believe Altimmune is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Altimmune	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Amphastar Pharmaceuticals beats Altimmune on 11 of the 19 factors compared between the two stocks.